Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2; it exhibits anti-inflammatory, analgesic, antiepileptic/anticonvulsant, and chemopreventive activities but is no longer clinically administered. Rofecoxib inhibits the formation of bladder tumors in FHIT models of bladder cancer carcinogenesis. Additionally, rofecoxib increases seizure threshold in an adenosine-dependent manner in vivo.
